These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27749324)

  • 21. [Hormonal therapy for advanced prostate cancer: current status and issues].
    Akakura K
    Nihon Rinsho; 2016 Jan; 74(1):124-8. PubMed ID: 26793892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Understanding heterogeneity of treatment effect in prostate cancer.
    Aly A; Mullins CD; Hussain A
    Curr Opin Oncol; 2015 May; 27(3):209-16. PubMed ID: 25689354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined androgen blockade: the gold standard for metastatic prostate cancer.
    McLeod DG; Crawford ED; DeAntoni EP
    Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.
    Sciarra A; Abrahamsson PA; Brausi M; Galsky M; Mottet N; Sartor O; Tammela TL; Calais da Silva F
    Eur Urol; 2013 Nov; 64(5):722-30. PubMed ID: 23628492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer.
    Diamond E; Garcias Mdel C; Karir B; Tagawa ST
    Curr Treat Options Oncol; 2015 Feb; 16(2):9. PubMed ID: 25762124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Emerging Role of Local Therapy in Metastatic Prostate Cancer.
    Sundahl N; Tree A; Parker C
    Curr Oncol Rep; 2020 Jan; 22(1):2. PubMed ID: 31960153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined hormone therapy and radiation therapy for locally advanced prostate cancer.
    Bolla M; Laramas M;
    Crit Rev Oncol Hematol; 2012 Dec; 84 Suppl 1():e30-4. PubMed ID: 21144766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update in systemic therapy of prostate cancer: improvement in quality and duration of life.
    Vaishampayan U; Hussain M
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):269-81. PubMed ID: 18279067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Role of hormonotherapy in the treatment of metastatic prostate cancer].
    Lebret T; Méjean A
    Prog Urol; 2008 Nov; 18 Suppl 7():S332-7. PubMed ID: 19070812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Actual benefit of chemo-hormonal therapy in non-castrate metastatic prostate cancer.
    Şendur MA; Akıncı MB; Ozdemir NY; Aksoy S; Dede DS; Ulas A; Zengin N; Yalçın B
    Future Oncol; 2015; 11(8):1141-3. PubMed ID: 25832870
    [No Abstract]   [Full Text] [Related]  

  • 32. Management of hormone-sensitive metastatic prostate cancer.
    Agarwal N; Hussain M
    Hematol Oncol Clin North Am; 2013 Dec; 27(6):1221-41, viii. PubMed ID: 24188260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Should we follow-up serum testosterone in patients with advanced prostate cancer?
    Perachino M
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1031-5. PubMed ID: 20645692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.
    Yu EY; Li H; Higano CS; Agarwal N; Pal SK; Alva A; Heath EI; Lam ET; Gupta S; Lilly MB; Inoue Y; Chi KN; Vogelzang NJ; Quinn DI; Cheng HH; Plymate SR; Hussain M; Tangen CM; Thompson IM
    J Clin Oncol; 2015 May; 33(14):1601-8. PubMed ID: 25847934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
    Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
    Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.
    Sava T; Basso U; Porcaro A; Cetto GL
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):53-62. PubMed ID: 15757438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Hormone therapy of locally advanced and metastatic prostate carcinoma].
    Rübben H
    Praxis (Bern 1994); 2001 Sep; 90(38):1641-4. PubMed ID: 11675917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
    MacVicar GR; Hussain MH
    Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic therapy for the treatment of hormone-sensitive metastatic prostate cancer: from intermittent androgen deprivation therapy to chemotherapy.
    Liaw BC; Shevach J; Oh WK
    Curr Urol Rep; 2015 Mar; 16(3):13. PubMed ID: 25677235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of metastatic hormone-sensitive prostate cancer.
    Bernard B; Sweeney CJ
    Curr Urol Rep; 2015 Mar; 16(3):14. PubMed ID: 25677237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.